ArticleObesity surgery2025
Metabolic Surgery for Obese Type 2 Diabetes: Korean Multicenter Cohort Study.
Article in Obesity surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
- Erratum issued
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic/bariatric surgery is an effective treatment for obesity and type 2 diabetes mellitus (T2DM), with sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) being the most common procedures. However, comparative data on their metabolic benefits in East Asian populations are limited.
methodsThis multicenter retrospective cohort study assessed outcomes of SG and RYGB in Korean adults (BMI ≥ 30 kg/m²) with T2DM who underwent surgery between January 2019 and June 2021. The primary outcome was complete T2DM remission at 1 and 2 years postoperatively. Follow-up data were available for 271 patients at 1 year and 169 at 2 years.
resultsUnadjusted analysis showed lower complete remission rates in the RYGB group than the SG group at both 1 year (51.4% vs. 66.3%, p = 0.029) and 2 years (50.0% vs. 62.9%, p = 0.033). After adjustment using inverse probability of treatment weighting (IPTW), the pattern reversed in favor of RYGB (1 year: 67.5% vs. 48.2%; 2 years: 64.4% vs. 46.9%), though differences were not statistically significant (p = 0.127 and p = 0.373). Multivariable logistic regression identified shorter duration of T2DM and absence of insulin use as independent predictors of remission; surgical procedure type was not.
conclusionsAfter adjusting for baseline differences, no statistically significant difference in T2DM remission was observed between SG and RYGB at 1 and 2 years in Korean patients with BMI ≥ 30 kg/m². These findings should be interpreted with caution given the modest sample size and limited follow-up. Prospective studies are needed to validate these findings and support clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.